UCA1 also recruits EZH2 to the promoter of CDKN1A/p21 gene to suppress its expression and activate the PI3K/Akt pathway, thereby contributing to tamoxifen resistance in breast cancers [218]. This evidence concerns the gene CDKN1A and breast carcinoma.